afabicin (Debio 1450)

Bone and joint infections

afabicin (Debio 1450) is a new antibiotic benefiting from both oral and IV formulations. It is a highly potent, staphylococcus-selective antibiotic with a low propensity to emergence of resistance. This first-in-class FabI inhibitor retains its activity on staphylococci strains resistant to antibiotics currently in clinical use including beta lactams, vancomycin, daptomycin or linezolid. Debio 1450, perfectly suited to tackle several hard-to-treat infections, is now in a Phase II trial involving patients with Bone & Joint infections (BJIs) caused by staphylococci.

Clinical trials

Press Releases

All Press Releases


All Publications